2008～2010年南京地区免疫抑制剂的利用分析

目的:评价2008～2010年南京地区免疫抑制剂的应用状况.方法:应用金额排序法和用药频度分析法,对南京地区27家医院2008～2010年临床使用的免疫抑制剂进行统计和分析.结果:2008～2010年南京地区免疫抑制剂用药总额依次为2 237.09万元,2 799.92万元及3 189.22万元,三年间金额逐年递增,平均增长率为19.51%,用药金额最大的是玛替麦考酚酯,构成比达到30%以上.用药频度(DDDs)逐年大幅度攀升,DDDs最大的是甲氨蝶呤.在抗排异药物中他克莫司(FK506)增长速度最快,三年来无论是金额还是DDDs都超过环孢素仅次于玛替麦考酚酯.免疫抑制剂中增长速度最快者为来氟米特,其使用金额一直稳居第4位,而DDDs逐年攀升,由2008年第3位升至2010年的第1位.结论:南京地区免疫抑制剂中抗排异药玛替麦考酚酯、他克莫司和环孢素为一线用药,其中以进口、合资企业产品为主.国产企业应努力迎头赶上,但随着国外重磅专利保护、行政保护的期满,国内企业机会增多,市场竞争会更加激烈,但市场前景会非常开阔.来氟米特作为新型免疫抑制剂,展示了良好的应用前景.

Application Analysis of Immunosuppressive Drugs in Nanjing Area during the Yearof 2008-2010

Objective： To evaluate the utilization status of immunosuppressive drugs in Nanjing area.Method： Data of immunosuppressive drugs utilization based on 27 hospitals in Nanjing area were collected and analyzed by the methods of consumption sum order and DDDs.Result： The consumption sum of immunosuppressive drugs in Nanjing area was 22 3709,27 9992 and 31 8922 million in the last three year with average yearly increase rate of 19.51%.The top one was mycophenolate with the proportion of 30%.DDDs also showed yearly increase with the top one of MTX.Moreover,Tacrolimus（FK506） exhibited the most rapied increase among anti-rejection drugs,which exceeded ciclosporin following the top one mycophenolate in both consumption sum and DDDs.Leflunomide showed the most rapied increase among immunosuppressive drugs in the fourth rank with DDDs from the third rank to the top.Conclusion： Immunosuppressive drugs from foreign and joint ventures occupy the leading position in Nanjing area.The domestic corporations should try hard to catch up.They could obtain more opportunity when the patent limit and administrated protection are over.Competition will be more intense while the market will be much wider in the near future.